Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial
Keros Therapeutics, Inc.
Keros Therapeutics Inc. (KROS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Logos Capital Arsani William | 2,000,000 | $20,380,000 | 3.62% | |
| 2. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 1,506,790 | $15,354,190 | +65% | 0.61% |
| 3. | ADAR1 Capital Management Daniel Schneeberger | 1,486,461 | $15,147,038 | +6295% | 2.81% |
| 4. | D E Shaw D. E. Shaw | 1,263,130 | $12,871,295 | +10340% | 0.01% |
| 5. | Tang Capital Management Kevin C. Tang | 1,100,000 | $11,209,000 | 0.62% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.33 | 74,333 | $767,859.89 | 4,392,737 | 2025-04-09 | Filing | |
| $10.33 | 500,000 | $5,165,000.00 | 4,318,404 | 2025-04-09 | Filing | |
| $9.86 | 325,000 | $3,203,525.00 | 3,818,404 | 2025-04-09 | Filing | |
| $9.40 | 16,365 | $153,752.45 | 743,558 | 2025-04-09 | Filing | |
| $9.40 | 18,560 | $174,374.91 | 3,493,404 | 2025-04-09 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $45.29 | 40,000 | $1,811,600.00 | 0 | 2024-01-04 | Filing | |
| $44.01 | 29,400 | $1,293,894.00 | 119,522 | 2024-08-13 | Filing | |
| $44.01 | 220,600 | $9,708,606.00 | 899,212 | 2024-08-13 | Filing | |
| $44.01 | 29,400 | $1,293,894.00 | 119,522 | 2024-08-13 | Filing | |
| $44.01 | 220,600 | $9,708,606.00 | 899,212 | 2024-08-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,947,455 | $94,525,877 | 0.03% | |
| 2. | 2,785,237 | $28,381,561 | 0% | |
| 3. | 2,600,457 | $26,498,658 | 0% | |
| 4. | 2,566,321 | $26,150,811 | 0% | |
| 5. | 1,697,557 | $17,298,106 | 0% |
News See All
13 Best Future Stocks for the Long-Term
Investing these days is a ride not for the faint hearted.
Hedge Fund and Insider Trading News: Archegos Capital Management, Autonomy Capital, Politan Capital Management, Lynx Asset Management, Sculptor Capital Management, Keros Therapeutics Inc (KROS), Liberty Sirius XM Group (LSXMA), and More
Assets have shrunk to $1.6 billion at the end of September. Fund struggling with Brazilian ‘inflation surprise’: documents.
Is KROS A Good Stock To Buy Now?
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns.
Hedge Fund and Insider Trading News: Chris Rokos, Cinctive Capital, Silver Lake Partners, Keros Therapeutics Inc (KROS), Ares Management Corp (ARES), and More
Billionaire Chris Rokos’s macro hedge fund had its best month ever, gaining 14% in March amid market chaos fueled by the coronavirus pandemic.
Billionaire Hedge Funds
